Compare LITB & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITB | FLNA |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | Singapore | United States |
| Employees | N/A | 20 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1M | 61.8M |
| IPO Year | 2013 | N/A |
| Metric | LITB | FLNA |
|---|---|---|
| Price | $3.23 | $1.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.8K | ★ 353.2K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.50 | N/A |
| Revenue Next Year | $11.59 | N/A |
| P/E Ratio | $10.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $0.86 |
| 52 Week High | $4.17 | $2.03 |
| Indicator | LITB | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.15 | 42.85 |
| Support Level | $2.81 | N/A |
| Resistance Level | $3.36 | $1.37 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 35.00 | 51.76 |
LightInTheBox Holding Co Ltd is a e-commerce company, providing a diverse range of affordable lifestyle products directly to consumers. Its brands include Ador, a women's fashion brand targeting women aged 35-55; the second is a golf apparel brand focusing on female golfers aged 35 and above; the third is a women's light party dress brand for the age group of 30 and above. It offers customers products through websites and mobile applications. The company operates and reviews its performance in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of the provision of logistic services to companies and individual customers.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.